Ewha Med J.  2015 Mar;38(1):46-49. 10.12771/emj.2015.38.1.46.

Ovarian Metastasis from Non-Small Cell Lung Cancer Responding to Erlotinib

• Jung IJ
• Lim ST
• Choi YS
• Jang TS
• Oh SH
• Lee JA
• Cho DY

• KMID: 2171329
• DOI: http://doi.org/10.12771/emj.2015.38.1.46

Abstract

Ovarian cancer is generally primary cancer and less frequently originates from metastasis from non-gynecological cancer. Ovarian metastasis from lung cancer represents only 2~4% of all ovarian metastatic cancers. We report a case of ovarian metastasis of non-small cell lung cancer with epidermal growth factor receptor mutation. The patient underwent cytoreductive surgery for the ovarian mass and erlotinib therapy for the metastatic lung cancer. Erlotinib therapy markedly decreased the size of lung mass.

Keyword

Non-small cell lung cancer; Metastasis; Erlotinib

MeSH Terms

Carcinoma, Non-Small-Cell Lung*
Humans
Lung
Lung Neoplasms
Neoplasm Metastasis*
Ovarian Neoplasms
Receptor, Epidermal Growth Factor
Erlotinib Hydrochloride
Receptor, Epidermal Growth Factor

Figure

• 

  Fig. 1 Abdomen and pelvis computed tomography. A 14.7×13.4 cm sized huge tumor of right ovary and peritoneal carcinomatosis are noted.

• 

  Fig. 2 Chest computed tomography. It reveals a 10×6 cm sized huge mass in left upper lung and massive right sided pleural effusion.

• 

  Fig. 3 Images taken after 2 cycles of gemcitabine with carboplatin chemotherapy. (A) Abdomen and pelvis computed tomography (CT) reveals increasing the size of left ovarian mass (20×14.5 cm). (B) Chest CT reveals increasing the size of left upper lung mass (12×8.2 cm).

• 

  Fig. 4 Immunohistochemical staining of the left ovary. (A) Cytokeratin-7 staining reveals strong reactivity (×100). (B) Thyroid transcription factor-1 staining reveals strong reactivity (×100).

• 

  Fig. 5 Chest CT after erlotinib chemotherapy. It reveals a marked decrease in the size of the left upper lung mass (4.2×3.7 cm).

Reference

1. Hart W. Diagnostic challenge of secondary (metastatic) ovarian tumors simulating primary endometrioid and mucinous neoplasms. Pathol Int. 2005; 55:231–243.

2. Horn L, Pao W, Johnson D. Neoplasm of the Lung. In : Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J, editors. Harrison's principles of internal medicine. 18th ed. New York: McGraw Hill;2012. p. 745–750.

3. Schiller J, Harrington D, Belani C, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346:92–98.

4. Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefetinib. N Engl J Med. 2004; 350:2129–2139.

5. Fader A, Rose P. Role of surgery in ovarian carcinoma. J Clin Oncol. 2007; 25:2873–2883.

6. Jung YE, Lee JW, Kim BG, Bae DS. Ovarian metastasis from pulmonary adenocarcinoma. Obstet Gynecol Sci. 2013; 56:341–344.

7. Varadhachary G, Abbruzzese J. Carcinoma of Unknown Primary. In : Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J, editors. Harrison's principles of internal medicine. 18th ed. New York: McGraw Hill;2012. p. 822–823.

8. Pfister D, Johnson D, Azzoli C, Sause W, Smith T, Baker S, et al. American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004; 22:330–353.

9. Hirsch F, Varella-Garcia M, Bunn P Jr, Franklin W, Dziadziuszko R, Thatcher N, et al. Molecular predictors of outcome with gefetinib in a phase III placebo-controlled study in advanced nonsmall-cell lung cancer. J Clin Oncol. 2006; 24:5034–5042.

10. Sequist L, Bell D, Lynch T, Haber D. Molecular predictors of response to epidermal growth factor receptor antagonists in nonsmall-cell lung cancer. J Clin Oncol. 2007; 25:587–595.